phone iconPhone: (401) 822-4673
phone iconFax: (401) 822-4676
Receive our Health e-Newsletter

News for Healthier Living

ESMO: New Analysis Reinforces Survival Benefits of Targeted Therapy for Advanced Pancreatic Cancer

A new analysis of a phase 3 clinical trial found that the targeted drug daraxonrasib improved survival compared with standard chemotherapy across multiple groups of patients with advanced pancreatic cancer, including those with different RAS mutations and those without an identified RAS mutation.

October 23, 2026


November 6 2026

November 5 2026

November 4 2026

November 3 2026

November 2 2026

November 1 2026

October 30 2026

October 29 2026

October 28 2026

October 27 2026

October 26 2026

October 25 2026

October 24 2026

October 23 2026

Angell Street Psychiatry
Copyright 2026 HealthBanks, Inc. All rights reserved.
Terms of Use | Privacy Policy